Information Provided By: 
Fly News Breaks for November 19, 2019
PGNY
Nov 19, 2019 | 06:06 EDT
Piper Jaffray analyst Sarah James initiated coverage of Progyny with an Overweight rating and $33 price target. Progyny is a disruptor in the fast growing $13B fertility market, James tells investors in a research note. She believes the company's "unique" benefit design and proprietary technology are driving share gains, savings, and better treatment outcomes.
News For PGNY From the Last 2 Days
There are no results for your query PGNY
